Table 2. Characteristics of 22 patients who underwent ICG-guided SLNB.

Study no.	Age	Menstrual state	Tumor location	Tumor size (cm)	cTNM	pTNM	ICG dose (ml)	SLN no.	SLN metastasis	ALN no.	ALN metastasis	Surgery
1	43	pre	Right upper outer	3×1.9	T2N1M0	T2N1M0	2	2	1/2	11	1/11	MRM +SLNB
2	46	pre	Left lower inner	1.2×0.8	T1N0M0	T1N0M0	1	1	0/1	32	0/32	BCS +ALND+SLNB
3	50	pre	Left upper outer	0.5×0.3	T1N0M0	T1N0M0	1	3	0/3	21	0/21	MRM +SLNB
4	68	post	Left upper outer	2.9×2.4	T2N1M0	T2N0M0	0.5	3	0/3	21	0/21	MRM +SLNB
5	38	pre	Left lower outer	1.8×0.6	T1N0M0	T1N0M0	1	1	0/1	18	0/18	MRM +SLNB
6	48	pre	Right upper outer	4.0×2.8	T2N1M0	T2N0M0	1	6	0/6	30	0/30	MRM +SLNB
7	66	post	Left upper inner	4.2×3.7	T2N1M0	T1N0M0	1	2	0/2	16	0/16	MRM +SLNB
8	47	pre	Left lower outer	5.7×1.6	T3N1M0	T3N2M0	1	3	1/3	25	4/25	MRM +SLNB
9	62	post	Left lower borderline	0.9×0.8	T1N0M0	T1N0M0	1	3	0/3	13	0/13	MRM +SLNB
10	55	post	Right upper inner	4.0×4.0	T2N1M0	T2N0M0	1	4	0/4	9	0/9	MRM +SLNB
11	59	post	Left upper inner	3.0×2.2	T2N1M0	T2N3M0	1	1	1/1	17	11/17	MRM +SLNB
12	67	post	Right upper outer	1.8×1.6	T1N0M0	T1N1M0	1	1	0/1	12	2/12	BCS +ALND+SLNB
13	32	pre	Right upper borderline	3.6×2.9	T2N1M0	T2N0M0	1	4	0/4	12	0/12	MRM +SLNB
14	40	pre	Left middle	1.8×1.2	T1N1M0	T2N0M0	2	4	0/4	10	0/10	MRM +SLNB
15	45	pre	Left lower outer	1.5×0.8	T1N0M0	T1N0M0	2	4	0/4	15	0/15	BCS +ALND+SLNB
16	57	post	Left lower outer	2.0×1.0	T2N0M0	T1N0M0	2	3	0/3	11	0/11	MRM +SLNB
17	33	pre	Right lower	2.3×1.2	T2N1M0	T2N1M0	2	4	1/4	20	0/20	MRM +SLNB
18	63	post	Left upper outer	2.4×2.6	T2N1M0	T2N0M0	2	3	0/3	5	0/5	MRM +SLNB
19	53	post	Right upper outer	2.5×1.7	T2N1M0	T2N1M0	2	2	1/2	14	0/14	MRM +SLNB
20	33	pre	Left upper outer	3.1×1.6	T2N0M0	T2N1M0	2	1	1/1	6	0/6	MRM +SLNB
21	50	post	Left upper	5.3×4.5	T3N1M0	T3N3M0	2	2	2/2	19	9/19	MRM +SLNB
22	43	pre	Left upper outer	1.6×1.2	T1N0M0	T1N0M0	2	2	0/2	24	0/24	MRM +SLNB

ALN axillary lymph node, ALND axillary lymph node dissection, SLNB sentinel lymph node biopsy, MRM modified radical mastectomy, BCS breast conserving surgery